

# Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

## Revvity: IVIS Spectrum 2 In Vivo Imaging System

RRID:SCR\_027425

Type: Tool

### Proper Citation

Revvity: IVIS Spectrum 2 In Vivo Imaging System (RRID:SCR\_027425)

### Resource Information

**URL:** <https://www.revvity.com/product/ivis-spectrum-2-imaging-system-cls158738>

**Proper Citation:** Revvity: IVIS Spectrum 2 In Vivo Imaging System (RRID:SCR\_027425)

**Description:** In vivo optical imaging system used in preclinical research to non-invasively monitor and quantify biological processes in living animals over time. Designed with innovative camera with patented coating that delivers high sensitivity 2D and 3D bioluminescence and fluorescence imaging capabilities.

**Synonyms:** IVIS Spectrum 2 In Vivo Imaging System

**Resource Type:** instrument resource

**Keywords:** Imaging instrument, in vivo imaging studies, 2D and 3D bioluminescence and fluorescence imaging,

**Specification URL:** [https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR\\_027425.pdf](https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR_027425.pdf)

**Resource Name:** Revvity: IVIS Spectrum 2 In Vivo Imaging System

**Resource ID:** SCR\_027425

**Alternate IDs:** Model\_Number\_IVIS\_Spectrum\_2

**Record Creation Time:** 20250913T055518+0000

**Record Last Update:** 20260808T190801+0000

### Ratings and Alerts

No rating or validation information has been found for Revvity: IVIS Spectrum 2 In Vivo Imaging System.

No alerts have been found for Revvity: IVIS Spectrum 2 In Vivo Imaging System.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Tanka AT, et al. (2026) Integrative CRISPR Screening and RNA Analyses Discover an Essential Role for PUF60 Interactions with 3' Splice Sites in Cancer Progression. Cancer research, 86(7), 1586.

Mart??n A, et al. (2026) Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. Cancer research.

Fang C, et al. (2026) Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. Cancer research, 86(8), 1956.